<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US6093748 - Applying to an area of skin from which reduced hair growth is desired a ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Applying to an area of skin from which reduced hair growth is desired a dermatologically acceptable composition containing a non-steroidal suppressor of angiogenesis"><meta name="DC.contributor" content="Gurpreet S. Ahluwalia" scheme="inventor"><meta name="DC.contributor" content="Peter Styczynski" scheme="inventor"><meta name="DC.contributor" content="Douglas Shander" scheme="inventor"><meta name="DC.contributor" content="Ahluwalia; Gurpreet S." scheme="assignee"><meta name="DC.contributor" content="Styczynski; Peter" scheme="assignee"><meta name="DC.contributor" content="Shander; Douglas" scheme="assignee"><meta name="DC.date" content="1997-11-3" scheme="dateSubmitted"><meta name="DC.description" content="A method of inhibiting hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatologically acceptable composition containing a non-steroidal suppressor of angiogenesis."><meta name="DC.date" content="2000-7-25" scheme="issued"><meta name="DC.relation" content="EP:0413528:A1" scheme="references"><meta name="DC.relation" content="EP:0532219:A2" scheme="references"><meta name="DC.relation" content="FR:2753375" scheme="references"><meta name="DC.relation" content="GB:1458349" scheme="references"><meta name="DC.relation" content="JP:H07112923" scheme="references"><meta name="DC.relation" content="US:3426137" scheme="references"><meta name="DC.relation" content="US:4039669" scheme="references"><meta name="DC.relation" content="US:4139638" scheme="references"><meta name="DC.relation" content="US:4161540" scheme="references"><meta name="DC.relation" content="US:4191775" scheme="references"><meta name="DC.relation" content="US:4269831" scheme="references"><meta name="DC.relation" content="US:4344941" scheme="references"><meta name="DC.relation" content="US:4370315" scheme="references"><meta name="DC.relation" content="US:4439432" scheme="references"><meta name="DC.relation" content="US:4720489" scheme="references"><meta name="DC.relation" content="US:4885289" scheme="references"><meta name="DC.relation" content="US:5095007" scheme="references"><meta name="DC.relation" content="US:5096911" scheme="references"><meta name="DC.relation" content="US:5132293" scheme="references"><meta name="DC.relation" content="US:5143925" scheme="references"><meta name="DC.relation" content="US:5189212" scheme="references"><meta name="DC.relation" content="US:5271942" scheme="references"><meta name="DC.relation" content="US:5300284" scheme="references"><meta name="DC.relation" content="US:5364885" scheme="references"><meta name="DC.relation" content="US:5378455" scheme="references"><meta name="DC.relation" content="US:5407944" scheme="references"><meta name="DC.relation" content="US:5554608" scheme="references"><meta name="DC.relation" content="US:5753612" scheme="references"><meta name="DC.relation" content="WO:1990012577:A2" scheme="references"><meta name="DC.relation" content="WO:1994004143:A1" scheme="references"><meta name="DC.relation" content="WO:1994027563:A1" scheme="references"><meta name="DC.relation" content="WO:1994027586:A1" scheme="references"><meta name="DC.relation" content="WO:1997041844:A1" scheme="references"><meta name="citation_reference" content="Ahluwalia, &quot;Method of Reducing the Rate of Hair Growth&quot;, U.S.S.N. 08/212,584, allowed."><meta name="citation_reference" content="Ahluwalia, Method of Reducing the Rate of Hair Growth , U.S.S.N. 08/212,584, allowed."><meta name="citation_reference" content="Alluwalia et al., &quot;Inhibition of Hair Growth&quot;, U.S.S.N. 08/213,954, allowed."><meta name="citation_reference" content="Alluwalia et al., Inhibition of Hair Growth , U.S.S.N. 08/213,954, allowed."><meta name="citation_reference" content="Arias et al., &quot;Effects of Cyproterone and Tamoxifen Upon the Hair Waves in Mice&quot;, Chemical Abstracts, 99:101, 1083, see abstract; ACTA Physiol. Latinoam., 32:261-266, 1982."><meta name="citation_reference" content="Arias et al., Effects of Cyproterone and Tamoxifen Upon the Hair Waves in Mice , Chemical Abstracts, 99:101, 1083, see abstract; ACTA Physiol. Latinoam., 32:261 266, 1982."><meta name="citation_reference" content="Borgstr o m et al., The quinoline 3 carboxamide Linomide inhibits angiogenesis in vivo , Cancer Chemotherapy and Pharmacology , 34:280 286 (1994)."><meta name="citation_reference" content="Borgstrom et al., &quot;The quinoline-3-carboxamide Linomide inhibits angiogenesis in vivo&quot;, Cancer Chemotherapy and Pharmacology, 34:280-286 (1994)."><meta name="citation_reference" content="Burdick et al., &quot;The Topical Effect of the Antiandrogen Chlormadin--One Acetate and Some of its . . . &quot;, Br. J. Derm., 82:19-25 Supplemetn 6, 19 (1970)."><meta name="citation_reference" content="Burdick et al., The Topical Effect of the Antiandrogen Chlormadin One Acetate and Some of its . . . , Br. J. Derm. , 82:19 25 Supplemetn 6, 19 (1970)."><meta name="citation_reference" content="CA113(15):126168f of Hear. Res. 46(1 2), 101 12 (1990)."><meta name="citation_reference" content="CA113(15):126168f of Hear. Res. 46(1-2), 101-12 (1990)."><meta name="citation_reference" content="Chang et al., &quot;Triazolinones as Nonpeptide Angiotensin II Antagonists. 2. Discovery of a Potent and . . . &quot;, Bioorganic &amp; Medicinal Chemistry Letters, 4:115-120 (1994)."><meta name="citation_reference" content="Chang et al., Triazolinones as Nonpeptide Angiotensin II Antagonists. 2. Discovery of a Potent and . . . , Bioorganic &amp; Medicinal Chemistry Letters , 4:115 120 (1994)."><meta name="citation_reference" content="Cohen, &quot;A platelet-activating factor antagonist reduces corneal allograft inflammation and neovascularization&quot;, Current Eye Research, 13:139-144 (1994)."><meta name="citation_reference" content="Cohen, A platelet activating factor antagonist reduces corneal allograft inflammation and neovascularization , Current Eye Research , 13:139 144 (1994)."><meta name="citation_reference" content="Fan et al., &quot;Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition . . . &quot;, Br. J. Pharmacol., 110:43-49 (1993)."><meta name="citation_reference" content="Fan et al., Stimulation of angiogenesis by substance P and interleukin 1 in the rat and its inhibition . . . , Br. J. Pharmacol. , 110:43 49 (1993)."><meta name="citation_reference" content="Folkman et al., &quot;Minireview: Angiogenesis&quot;, The Journal of Biological Chemistry, 267:10931-10934 (1992)."><meta name="citation_reference" content="Folkman et al., Minireview: Angiogenesis , The Journal of Biological Chemistry , 267:10931 10934 (1992)."><meta name="citation_reference" content="Golditch et al. Treatment of Hirsutism with Cimetidine. Obstetrics &amp; Gynecology, vol. 75, No. 6, pp. 911 913. Jun. 1990."><meta name="citation_reference" content="Golditch et al. Treatment of Hirsutism with Cimetidine. Obstetrics &amp; Gynecology, vol. 75, No. 6, pp. 911-913. Jun. 1990."><meta name="citation_reference" content="Goos et al., &quot;An Improved Method for Evaluating Antiandrogens&quot;, Arch. Dermatol. Res., 273:333-341 (1982)."><meta name="citation_reference" content="Goos et al., An Improved Method for Evaluating Antiandrogens , Arch. Dermatol. Res. , 273:333 341 (1982)."><meta name="citation_reference" content="Gullino, &quot;Considerations on the Mechanism of the Angiogenic Response&quot;, Anticancer Research, 6:153-158 (1986)."><meta name="citation_reference" content="Gullino, Considerations on the Mechanism of the Angiogenic Response , Anticancer Research , 6:153 158 (1986)."><meta name="citation_reference" content="Harmon et al., &quot;12-O-Tetradecanoylphorbol-13-Acetate Inhibits Human Hair Follicle Growth and Hair Fiber Production in Whole-Organ Cultures&quot;, SID Abstracts, 102:533 (Apr., 1994)."><meta name="citation_reference" content="Harmon et al., 12 O Tetradecanoylphorbol 13 Acetate Inhibits Human Hair Follicle Growth and Hair Fiber Production in Whole Organ Cultures , SID Abstracts , 102:533 (Apr., 1994)."><meta name="citation_reference" content="Laniado Schwartzman et al., Activation Nuclear Factor kB and Oncogene Expression by 12(R) Hydroxyeicosatrienoic Acid . . . , The Journal of Biological Chemistry , 269:24321 24327 (1994)."><meta name="citation_reference" content="Laniado-Schwartzman et al., &quot;Activation Nuclear Factor kB and Oncogene Expression by 12(R)-Hydroxyeicosatrienoic Acid . . . &quot;, The Journal of Biological Chemistry, 269:24321-24327 (1994)."><meta name="citation_reference" content="Le Noble et al., &quot;Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo&quot;, European Journal of Pharmacology, 195:305-306 (1991)."><meta name="citation_reference" content="Le Noble et al., Angiotensin II stimulates angiogenesis in the chorio allantoic membrane of the chick embryo , European Journal of Pharmacology , 195:305 306 (1991)."><meta name="citation_reference" content="Li et al., &quot;Diminished Heparin Binding of a Basic Fibroblast Growth Factor Mutant Is Associated with . . . &quot;, Biochemistry, 33:10999-11007 (1994)."><meta name="citation_reference" content="Li et al., Diminished Heparin Binding of a Basic Fibroblast Growth Factor Mutant Is Associated with . . . , Biochemistry , 33:10999 11007 (1994)."><meta name="citation_reference" content="Lissak et al. Treatment of Hirsutism with Cimetidine: A Prospective Randomized Controlled Trial. Fertil Steril. vol. 51, No. 2, pp. 247 250. Feb. 1989."><meta name="citation_reference" content="Lissak et al. Treatment of Hirsutism with Cimetidine: A Prospective Randomized Controlled Trial. Fertil-Steril. vol. 51, No. 2, pp. 247-250. Feb. 1989."><meta name="citation_reference" content="Majewski et al., &quot;Relationship Between the Hair Growth Cycle and the Intensity of Lymphocyte-Induced Angiogenesis in Mouse Skin&quot;, 277:77-78, 1985."><meta name="citation_reference" content="Majewski et al., Relationship Between the Hair Growth Cycle and the Intensity of Lymphocyte Induced Angiogenesis in Mouse Skin , 277:77 78, 1985."><meta name="citation_reference" content="Messenger, &quot;The Control of Hair Growth: An Overview&quot;, Journal of Investigative Dermatology, 101:4S-9S (Jul., 1993)."><meta name="citation_reference" content="Messenger, The Control of Hair Growth: An Overview , Journal of Investigative Dermatology , 101:4S 9S (Jul., 1993)."><meta name="citation_reference" content="Nguyen et al., &quot;Pentosan Inhibits Angiogenesis In Vitro and Suppresses Prostate Tumor Growth In Vivo&quot;, Chemical Abstracts, 120:35, 1994, see abstract; Anticancer Research, 13:2143-2147, 1993."><meta name="citation_reference" content="Nguyen et al., Pentosan Inhibits Angiogenesis In Vitro and Suppresses Prostate Tumor Growth In Vivo , Chemical Abstracts, 120:35, 1994, see abstract; Anticancer Research, 13:2143 2147, 1993."><meta name="citation_reference" content="Notification of Transmittal of The International Search Report or the Declaration (8 pages)."><meta name="citation_reference" content="Paus, &quot;Hair Grwoth Inhibition by Heparin in Mice: A Model System for Studying the Modulation of Epithelial Cell Growth by Glucosaminoglycans?&quot;, British Journal of Dermatology, 124:415-422, 1991."><meta name="citation_reference" content="Paus, Hair Grwoth Inhibition by Heparin in Mice: A Model System for Studying the Modulation of Epithelial Cell Growth by Glucosaminoglycans , British Journal of Dermatology, 124:415 422, 1991."><meta name="citation_reference" content="Poss et al., &quot;1,4-Substituted Indoles: A Potent and Selective Class of Angiotensin II Receptor Antagonists&quot;, Bioorganic &amp; Medicinal Chemistry Letters, 4:145-150 (1994)."><meta name="citation_reference" content="Poss et al., 1,4 Substituted Indoles: A Potent and Selective Class of Angiotensin II Receptor Antagonists , Bioorganic &amp; Medicinal Chemistry Letters , 4:145 150 (1994)."><meta name="citation_reference" content="Raju et al., &quot;Ceruloplasmin, Copper Ions, and Angiogenesis1,2 &quot;, JNCI, 69:1183-1188."><meta name="citation_reference" content="Raju et al., Ceruloplasmin, Copper Ions, and Angiogenesis 1,2 , JNCI , 69:1183 1188."><meta name="citation_reference" content="Sato, &quot;The Hair Cycle and its Control Mechanism&quot;, Biology and Disease of the Hair, 3-13 (1975)."><meta name="citation_reference" content="Sato, The Hair Cycle and its Control Mechanism , Biology and Disease of the Hair , 3 13 (1975)."><meta name="citation_reference" content="Shander et al., &quot;Method of Reducing Hair Growth Employing Sulfhydryl Active Compounds&quot;, U.S. Patent No. 5,411,991, issued May 2, 1995."><meta name="citation_reference" content="Shander et al., Method of Reducing Hair Growth Employing Sulfhydryl Active Compounds , U.S. Patent No. 5,411,991, issued May 2, 1995."><meta name="citation_reference" content="Siegl et al., &quot;In Vivo Pharmacology of L-158,809, a New Highly Potent and Selective Nonpeptide . . . &quot;, The Journal of Pharmacology and Experimental Therapeutics, 262:139-144 (1992)."><meta name="citation_reference" content="Siegl et al., In Vivo Pharmacology of L 158,809, a New Highly Potent and Selective Nonpeptide . . . , The Journal of Pharmacology and Experimental Therapeutics , 262:139 144 (1992)."><meta name="citation_reference" content="Simpson et al., &quot;The effect of topically applied progesterone on sebum excretion rate&quot;, British Journal, of Dermatology, 100:687-692 (1979)."><meta name="citation_reference" content="Simpson et al., The effect of topically applied progesterone on sebum excretion rate , British Journal, of Dermatology , 100:687 692 (1979)."><meta name="citation_reference" content="Sorbo et al., &quot;Mast-cell histamine is angiogenic through receptors for histamine1 and histamine2 &quot;, Int. J. Exp. Path., 75:43-50 (1994)."><meta name="citation_reference" content="Sorbo et al., Mast cell histamine is angiogenic through receptors for histamine 1 and histamine 2 , Int. J. Exp. Path. , 75:43 50 (1994)."><meta name="citation_reference" content="Takano et al., &quot;A Diaminoanthraquinone Inhibitor of Angiogenesis&quot;, The Journal of Pharmacology and Experimental Therapeutics, 271:1027-1033 (1994)."><meta name="citation_reference" content="Takano et al., A Diaminoanthraquinone Inhibitor of Angiogenesis , The Journal of Pharmacology and Experimental Therapeutics , 271:1027 1033 (1994)."><meta name="citation_reference" content="Ushmorov et al., &quot;Effects of Complete and Imcomplete Tumor Promoters on Hair Growth, Angiogenesis, and Tenascin Expression in the Skin of NMRI Mice&quot;, Carcinogenesis, 15:2739-2745, 1994."><meta name="citation_reference" content="Ushmorov et al., Effects of Complete and Imcomplete Tumor Promoters on Hair Growth, Angiogenesis, and Tenascin Expression in the Skin of NMRI Mice , Carcinogenesis, 15:2739 2745, 1994."><meta name="citation_reference" content="Wester et al., &quot;Dihydropyridines: A New Class of Angiotensin II Antagonists&quot;, Bioorganic &amp; Medicinal Chemistry Letters, 4:133-138 (1994)."><meta name="citation_reference" content="Wester et al., Dihydropyridines: A New Class of Angiotensin II Antagonists , Bioorganic &amp; Medicinal Chemistry Letters , 4:133 138 (1994)."><meta name="citation_reference" content="Westgate et al., &quot;Distribution of Proteoglycans During the Hair Growth Cycle in Human Skin&quot;, The J. of Investigative Dermatology, 96:191-195, 1991."><meta name="citation_reference" content="Westgate et al., Distribution of Proteoglycans During the Hair Growth Cycle in Human Skin , The J. of Investigative Dermatology, 96:191 195, 1991."><meta name="citation_reference" content="Ziche et al., &quot;Role of Prostaglandin E1 and Copper in Angiogenesis1,2 &quot;, JNCI, 69:475-480 (1982)."><meta name="citation_reference" content="Ziche et al., Role of Prostaglandin E 1 and Copper in Angiogenesis 1,2 , JNCI , 69:475 480 (1982)."><meta name="citation_patent_number" content="US:6093748"><meta name="citation_patent_application_number" content="US:08/963,227"><link rel="canonical" href="http://www.google.com/patents/US6093748"/><meta property="og:url" content="http://www.google.com/patents/US6093748"/><meta name="title" content="Patent US6093748 - Applying to an area of skin from which reduced hair growth is desired a dermatologically acceptable composition containing a non-steroidal suppressor of angiogenesis"/><meta name="description" content="A method of inhibiting hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatologically acceptable composition containing a non-steroidal suppressor of angiogenesis."/><meta property="og:title" content="Patent US6093748 - Applying to an area of skin from which reduced hair growth is desired a dermatologically acceptable composition containing a non-steroidal suppressor of angiogenesis"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("EaHtU_7-F5HFsASMnoCgCw"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("USA"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("EaHtU_7-F5HFsASMnoCgCw"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("USA"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us6093748?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US6093748"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=T2pQBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS6093748&amp;usg=AFQjCNE1xUTaaZpJMW4RpzwkSG3tNd2sFw" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US6093748.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US6093748.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US6093748" style="display:none"><span itemprop="description">A method of inhibiting hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatologically acceptable composition containing a non-steroidal suppressor of angiogenesis....</span><span itemprop="url">http://www.google.com/patents/US6093748?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US6093748 - Applying to an area of skin from which reduced hair growth is desired a dermatologically acceptable composition containing a non-steroidal suppressor of angiogenesis</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US6093748 - Applying to an area of skin from which reduced hair growth is desired a dermatologically acceptable composition containing a non-steroidal suppressor of angiogenesis" title="Patent US6093748 - Applying to an area of skin from which reduced hair growth is desired a dermatologically acceptable composition containing a non-steroidal suppressor of angiogenesis"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US6093748 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/963,227</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Jul 25, 2000</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Nov 3, 1997</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Feb 28, 1995</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2213404A1">CA2213404A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2213404C">CA2213404C</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69622154D1">DE69622154D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69622154T2">DE69622154T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0812185A2">EP0812185A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0812185B1">EP0812185B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1996026712A2">WO1996026712A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1996026712A3">WO1996026712A3</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08963227, </span><span class="patent-bibdata-value">963227, </span><span class="patent-bibdata-value">US 6093748 A, </span><span class="patent-bibdata-value">US 6093748A, </span><span class="patent-bibdata-value">US-A-6093748, </span><span class="patent-bibdata-value">US6093748 A, </span><span class="patent-bibdata-value">US6093748A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Gurpreet+S.+Ahluwalia%22">Gurpreet S. Ahluwalia</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Peter+Styczynski%22">Peter Styczynski</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Douglas+Shander%22">Douglas Shander</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Ahluwalia%3B+Gurpreet+S.%22">Ahluwalia; Gurpreet S.</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Styczynski%3B+Peter%22">Styczynski; Peter</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Shander%3B+Douglas%22">Shander; Douglas</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US6093748.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6093748.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6093748.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (33),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (69),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (24),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (77),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (5)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/6093748&usg=AFQjCNFF0y8k1RA_KCLJ_nCba5SlSNr24A">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D6093748&usg=AFQjCNGaKD4fDUbJRAzLWLqAaIacwg_SsA">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D6093748A%26KC%3DA%26FT%3DD&usg=AFQjCNEKBPtNDVGY7rwZ2_bv5Ph0v4_BwA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT129053020" lang="EN" load-source="ifi">Applying to an area of skin from which reduced hair growth is desired a dermatologically acceptable composition containing a non-steroidal suppressor of angiogenesis</invention-title></span><br><span class="patent-number">US 6093748 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA38100613" lang="EN" load-source="patent-office"> <div class="abstract">A method of inhibiting hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatologically acceptable composition containing a non-steroidal suppressor of angiogenesis.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(1)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6093748-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6093748-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(88)</span></span></div><div class="patent-text"><div mxw-id="PCLM59572805" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>We claim:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A method of reducing human androgen-stimulated hair growth which comprises<div class="claim-text">selecting an area of skin on a human from which reduced androgen-stimulated hair growth is desired; and</div> <div class="claim-text">applying to said area of skin a dermatologically acceptable composition comprising a non-steroidal suppressor of angiogenesis in an amount effective to reduce androgen-stimulated hair growth.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. The method of claim 1, wherein said suppressor is a compound that interferes with the action of heparin sulfate proteoglycans.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. The method of claim 2, wherein said compound is an inhibitor of sulfotransferase.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. The method of claim 2, wherein said compound is a heparin binding antagonist.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. The method of claim 2, wherein said compound is a copper chelator.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. The method of claim 1, wherein said suppressor is a compound that interferes with the action of histamine.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. The method of claim 6, wherein said compound is an inhibitor of histidine decarboxylase.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. The method of claim 1, wherein said suppressor is a compound that is an inhibitor of mast cell degranulation.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. The method of claim 6, wherein said compound is a histamine receptor antagonist.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. The method of claim 1, wherein said suppressor is a compound that interferes with the action of angiotensin II.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" class="claim">
      <div class="claim-text">11. The method of claim 10, wherein said compound is an inhibitor of angiotensin converting enzyme.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" class="claim">
      <div class="claim-text">12. The method of claim 10, wherein said compound is an angiotensin II receptor antagonist.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" class="claim">
      <div class="claim-text">13. The method of claim 1, wherein said suppressor is a compound that interferes with the action of prostaglandin E1.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="14" class="claim">
      <div class="claim-text">14. The method of claim 1, wherein said suppressor is a compound that is an inhibitor of prostaglandin synthetase.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="15" class="claim">
      <div class="claim-text">15. The method of claim 1 wherein said suppressor interferes with the action of Substance P.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="16" class="claim">
      <div class="claim-text">16. The method of claim 15, wherein said compound is an NK1 receptor antagonist.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="17" class="claim">
      <div class="claim-text">17. The method of claim 1, wherein said suppressor interferes with the action of platelet activating factor.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="18" class="claim">
      <div class="claim-text">18. The method of claim 17, wherein said compound is a platelet activating factor receptor antagonist.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="19" class="claim">
      <div class="claim-text">19. The method of claim 1, wherein said suppressor interferes with the action of 12-HETrE.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="20" class="claim">
      <div class="claim-text">20. The method of claim 19, wherein said compound is an inhibitor of cytochrome P450 reductase.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="21" class="claim">
      <div class="claim-text">21. The method of claim 1, wherein said composition further comprises vehicle.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="22" class="claim">
      <div class="claim-text">22. The method of claim 1, wherein the concentration of said suppressor in said composition is between 1% and 30% by weight.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="23" class="claim">
      <div class="claim-text">23. The method of claim 1, wherein the composition provides a reduction in hair growth of at least 20% when tested in the Golden Syrian hamster assay.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="24" class="claim">
      <div class="claim-text">24. The method of claim 1, wherein the composition provides a reduction in hair growth of at least 50% when tested in the Golden Syrian hamster assay.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="25" class="claim">
      <div class="claim-text">25. The method of claim 1, wherein the composition provides a reduction in hair growth of at least 70% when tested in the Golden Syrian hamster assay.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="26" class="claim">
      <div class="claim-text">26. The method of claim 1, wherein the suppressor is applied to the skin in an amount of from 100 to 3000 micrograms of said inhibitor per square centimeter of skin.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="27" class="claim">
      <div class="claim-text">27. The method of claim 1, wherein said area of skin is on the face of the human.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="28" class="claim">
      <div class="claim-text">28. The method of claim 27, wherein said human is a woman suffering from hirsutism.</div>
    </div>
    </div> <div class="claim"> <div num="29" class="claim">
      <div class="claim-text">29. A method of reducing mammalian hair growth which comprises<div class="claim-text">selecting an area of skin from which reduced hair growth is desired; and</div> <div class="claim-text">applying topically to said area of skin a dermatologically acceptable composition comprising an inhibitor of sulfotransferase in an amount effective to reduce hair growth.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="30" class="claim">
      <div class="claim-text">30. The method of claim 29, wherein said inhibitor is p-nitrocatechol.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="31" class="claim">
      <div class="claim-text">31. The method of claim 29, wherein said inhibitor is catechin.</div>
    </div>
    </div> <div class="claim"> <div num="32" class="claim">
      <div class="claim-text">32. A method of reducing mammalian hair growth which comprises<div class="claim-text">selecting an area of skin from which reduced hair growth is desired; and</div> <div class="claim-text">applying topically to said area of skin a dermatologically acceptable composition comprising a heparin binding antagonist in an amount effective to reduce hair growth.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="33" class="claim">
      <div class="claim-text">33. The method of claim 32, wherein said antagonist is pentosan polysulfate.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="34" class="claim">
      <div class="claim-text">34. The method of claim 32, wherein said antagonist is quinacrine.</div>
    </div>
    </div> <div class="claim"> <div num="35" class="claim">
      <div class="claim-text">35. A method of reducing mammalian hair growth which comprises<div class="claim-text">selecting an area of skin from which reduced hair growth is desired; and</div> <div class="claim-text">applying topically to said area of skin a dermatologically acceptable composition comprising a copper chelator in an amount effective to reduce hair growth.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="36" class="claim">
      <div class="claim-text">36. The method of claim 35, wherein said copper chelator is bathocuproine disulfonate.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="37" class="claim">
      <div class="claim-text">37. The method of claim 35, wherein said copper chelator is diethylenetriamine pentaacetic acid.</div>
    </div>
    </div> <div class="claim"> <div num="38" class="claim">
      <div class="claim-text">38. A method of reducing mammalian hair growth which comprises<div class="claim-text">selecting an area of skin from which reduced hair growth is desired; and</div> <div class="claim-text">applying to said area of skin a dermatologically acceptable composition comprising an inhibitor of histidine decarboxylase in an amount effective to reduce hair growth.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="39" class="claim">
      <div class="claim-text">39. The method of claim 38, wherein said inhibitor is O-p-nitrohydroxylamine.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="40" class="claim">
      <div class="claim-text">40. The method of claim 38, wherein said inhibitor is -fluoromethylhistidine.</div>
    </div>
    </div> <div class="claim"> <div num="41" class="claim">
      <div class="claim-text">41. A method of reducing human androgen-stimulated hair growth which comprises<div class="claim-text">selecting an area of skin on a human from which reduced androgen-stimulated hair growth is desired; and</div> <div class="claim-text">applying to said area of skin a dermatologically acceptable composition comprising an inhibitor of mast cell degranulation in an amount effective to reduce androgen-stimulated hair growth.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="42" class="claim">
      <div class="claim-text">42. The method of claim 41, wherein said inhibitor is mycophenolic acid.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="43" class="claim">
      <div class="claim-text">43. The method of claim 41, wherein said inhibitor is bromocryptine.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="44" class="claim">
      <div class="claim-text">44. The method of claim 41, wherein said inhibitor is cromoglycate.</div>
    </div>
    </div> <div class="claim"> <div num="45" class="claim">
      <div class="claim-text">45. A method of reducing mammalian hair growth which comprises<div class="claim-text">selecting an area of skin from which reduced hair growth is desired; and</div> <div class="claim-text">applying topically to said area of skin a dermatologically acceptable composition comprising a histamine receptor antagonist in an amount effective to reduce hair growth.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="46" class="claim">
      <div class="claim-text">46. The method of claim 45, wherein said antagonist is terfenadine.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="47" class="claim">
      <div class="claim-text">47. The method of claim 45, wherein said antagonist is tripelennamine.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="48" class="claim">
      <div class="claim-text">48. The method of claim 45, wherein said antagonist is chlorpheniramine.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="49" class="claim">
      <div class="claim-text">49. The method of claim 45, wherein said antagonist is cimetidine.</div>
    </div>
    </div> <div class="claim"> <div num="50" class="claim">
      <div class="claim-text">50. A method of reducing mammalian hair growth which comprises<div class="claim-text">selecting an area of skin from which reduced hair growth is desired; and</div> <div class="claim-text">applying topically to said area of skin a dermatologically acceptable composition comprising an inhibitor of angiotensin converting enzyme in an amount effective to reduce hair growth.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="51" class="claim">
      <div class="claim-text">51. The method of claim 50, wherein said inhibitor is enalapril.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="52" class="claim">
      <div class="claim-text">52. The method of claim 50, wherein said inhibitor is lisinopril.</div>
    </div>
    </div> <div class="claim"> <div num="53" class="claim">
      <div class="claim-text">53. A method of reducing mammalian hair growth which comprises<div class="claim-text">selecting an area of skin from which reduced hair growth is desired; and</div> <div class="claim-text">applying topically to said area of skin a dermatologically acceptable composition comprising an angiotensin II receptor antagonist in an amount effective to reduce hair growth.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="54" class="claim">
      <div class="claim-text">54. The method of claim 53, wherein said antagonist is a 1,4-substituted indole.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="55" class="claim">
      <div class="claim-text">55. The method of claim 53, wherein said antagonist is a dihydropyridine derivative.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="56" class="claim">
      <div class="claim-text">56. The method of claim 55, wherein said antagonist is nifedipine.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="57" class="claim">
      <div class="claim-text">57. The method of claim 53, wherein said antagonist is a triazolinone derivative.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="58" class="claim">
      <div class="claim-text">58. The method of claim 57, wherein said triazolinane derivative has a side chain at the N<sup>4</sup> position.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="59" class="claim">
      <div class="claim-text">59. The method of claim 53, wherein said antagonist is a tetrahydroisoquinoline carboxylic acid.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="60" class="claim">
      <div class="claim-text">60. The method of claim 53, wherein said antagonist is an imidazopyridine derivative.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="61" class="claim">
      <div class="claim-text">61. The method of claim 60, wherein said imidazopyridine derivative is a tetrahydroimidazopyridine carboxylic acid analog.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="62" class="claim">
      <div class="claim-text">62. The method of claim 53, wherein said antagonist is Losantan.</div>
    </div>
    </div> <div class="claim"> <div num="63" class="claim">
      <div class="claim-text">63. A method of reducing mammalian hair growth which comprises<div class="claim-text">selecting an area of skin from which reduced hair growth is desired; and</div> <div class="claim-text">applying topically to said area of skin a dermatologically acceptable composition comprising an inhibitor of prostaglandin synthetase in an amount effective to reduce hair growth.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="64" class="claim">
      <div class="claim-text">64. The method of claim 63, wherein said inhibitor is piracetam.</div>
    </div>
    </div> <div class="claim"> <div num="65" class="claim">
      <div class="claim-text">65. A method of reducing mammalian hair growth which comprises<div class="claim-text">selecting an area of skin from which reduced hair growth is desired; and</div> <div class="claim-text">applying topically to said area of skin a dermatologically acceptable composition comprising an NK<sup>1</sup> receptor antagonist in an amount effective to reducing hair growth.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="66" class="claim">
      <div class="claim-text">66. The method of claim 65, wherein said antagonist is (3aR,7aR)-7,7,-diphenyl-2-[1-imino-2-(2-methoxyphenyl)ethyl]perhydroisoindol-4-one.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="67" class="claim">
      <div class="claim-text">67. The method of claim 65, wherein said antagonist is cis-2-(diphenylmethyl)-N-[(2-methoxy-phenyl)]-methyl]-1-azabicyclo[2,2,2]octan-3-amine.</div>
    </div>
    </div> <div class="claim"> <div num="68" class="claim">
      <div class="claim-text">68. A method of reducing mammalian hair growth which comprises<div class="claim-text">selecting an area of skin from which reduced hair growth is desired; and</div> <div class="claim-text">applying topically to said area of skin a dermatologically acceptable composition comprising a platelet activating factor receptor antagonist in an amount effective to reduce hair growth.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="69" class="claim">
      <div class="claim-text">69. The method of claim 68, wherein said antagonist is tioconazole.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="70" class="claim">
      <div class="claim-text">70. The method of claim 68, wherein said antagonist is (3-[4-(2-chlorphenyl)-9-methyl-6H-thieno[2-f]-[1,2,4]triazolo-[4,3-a][1,4]-diazepin-2-yl-1-(4-morpholinyl)-1-propanone.</div>
    </div>
    </div> <div class="claim"> <div num="71" class="claim">
      <div class="claim-text">71. A method of reducing mammalian hair growth which comprises<div class="claim-text">selecting an area of skin from which reduced hair growth is desired; and</div> <div class="claim-text">applying topically to said area of skin a dermatologically acceptable composition comprising an inhibitor of cytochrome P450 reductase in an amount effective to reduce hair growth.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="72" class="claim">
      <div class="claim-text">72. The method of claim 71, wherein said inhibitor is clotrimazole.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="73" class="claim">
      <div class="claim-text">73. The method of claim 1 or 41, wherein said area of skin comprises the beard area.</div>
    </div>
    </div> <div class="claim"> <div num="74" class="claim">
      <div class="claim-text">74. A method of reducing mammalian hair growth which comprises<div class="claim-text">selecting an area of skin from which reduced hair growth is desired; and</div> <div class="claim-text">applying topically to said area of skin a dermatologically acceptable composition comprising, in an amount effective to reduce hair growth, a compound selected from the group consisting of tamoxifen; nafoxidine; irsogladine; the synthetic laminin peptide, CDPGYIGSR-NH<sub>2</sub> ; radicicol; eponemycin; fumagillin (O-(chloroacetyl-carbamoyl)fumagillol) and synthetic analogues thereof; recombinant human platelet factor-4 and related peptides; protamine; sulfated chitin derivatives; diaminoanthraquinone derivatives; thrombospondin; quinoline-3-carboxamide (linomide); analogues of diatamycin A; and aurintricarboxylic acid.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="75" class="claim">
      <div class="claim-text">75. The method of claim 74, wherein said compound is tamoxifen.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="76" class="claim">
      <div class="claim-text">76. The method of claim 74, wherein said compound is nafoxidine.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="77" class="claim">
      <div class="claim-text">77. The method of claim 74, wherein said compound is CDPGYIGSR-NH<sub>2</sub>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="78" class="claim">
      <div class="claim-text">78. The method of claim 74, wherein said compound is radicicol.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="79" class="claim">
      <div class="claim-text">79. The method of claim 74, wherein said compound is eponemycin.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="80" class="claim">
      <div class="claim-text">80. The method of claim 74, wherein said compound is fumagillin.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="81" class="claim">
      <div class="claim-text">81. The method of claim 74, wherein said compound is recombinant human platelet factor-4.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="82" class="claim">
      <div class="claim-text">82. The method of claim 74, wherein said compound is protamine.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="83" class="claim">
      <div class="claim-text">83. The method of claim 74, wherein said compound is thrombospondin.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="84" class="claim">
      <div class="claim-text">84. The method of claim 74, wherein said compound is quinoline-3-carboxamide.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="85" class="claim">
      <div class="claim-text">85. The method of claim 74, wherein said compound is aurintricarboxylic acid.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="86" class="claim">
      <div class="claim-text">86. The method of claim 29, 32, 35, 38, 45, 50, 53, 63, 65, 68, 71, or 74, wherein said area of skin is on a human.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="87" class="claim">
      <div class="claim-text">87. The method of claim 1, 29, 32, 35, 38, 41, 45, 50, 53, 63, 65, 68, 71, or 74, wherein said area of skin is on the face or body of a human.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="88" class="claim">
      <div class="claim-text">88. The method of claim 1, 29, 32, 35, 38, 41, 45, 50, 53, 63, 65, 68, 71, or 74, wherein said area of skin is on a human and said hair growth comprises androgen-stimulated hair growth.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES67506045" lang="EN" load-source="patent-office" class="description">
    <p>This is a continuation of application Ser. No. 08/396,446, filed Feb. 28, 1995, now abandoned.</p>
    <heading>BACKGROUND</heading> <p>The invention relates to a method of the inhibition of unwanted hair growth in mammals.</p>
    <p>A main function of mammalian hair is to provide environmental protection. However, that function has largely been lost in humans, in whom hair is kept or removed from various parts of the body essentially for cosmetic reasons. For example, it is generally preferred to have hair on the scalp but not on the face.</p>
    <p>Various procedures have been employed to remove unwanted hair, including shaving, electrolysis, depilatory creams or lotions, waxing, plucking, and therapeutic antiandrogens. These conventional procedures generally have drawbacks associated with them. Shaving, for instance, can cause nicks and cuts, and can leave a perception of an increase in the rate of hair regrowth. Shaving also can leave an undesirable stubble. Electrolysis, on the other hand, can keep a treated area free of hair for prolonged periods of time, but can be expensive, painful, and sometimes leaves scarring. Depilatory creams, though very effective, typically are not recommended for frequent use due to their high irritancy potential. Waxing and plucking can cause pain, discomfort, and poor removal of short hair. Finally, antiandrogens--which have been used to treat female hirsutism--can have unwanted side effects.</p>
    <p>It has previously been disclosed that the rate and character of hair growth can be altered by applying to the skin inhibitors of certain enzymes. These inhibitors include inhibitors of 5-alpha reductase, ornithine decarboxylase, S-adenosylmethionine decarboxylase, gamma-glutamyl transpeptidase, and transglutaminase. See, for example, Breuer et al., U.S. Pat. No. 4,885,289; Shander, U.S. Pat. No. 4,720,489; Ahluwalia, U.S. Pat. No. 5,095,007; Ahluwalia et al., U.S. Pat. No. 5,096,911; Shander et al., U.S. Pat. No. 5,132,293; and Shander et al., U.S. Pat. No. 5,143,925.</p>
    <p>Angiogenesis, the development of new blood vessels, is the cumulative effect of many biochemical processes and occurs mainly during embryonic growth, wound healing, and the cyclical development of the uterine endometrium. Angiogenesis also plays a role in diabetic retinopathy, atherosclerosis, and tumor growth. Angiogenesis involves the degradation of both the parent vessel basement membrane and the interstitial matrix to provide a passage for the new vessel; migration of endothelial cells toward an angiogenic stimulus; formation of a lumen and the initiation of blood flow. These processes are under the control of growth factors, cytokines, peptides, immunomodulators, as well as other factors that may act as direct stimulants of angiogenesis or as indirect stimulants by attracting inflammatory factors.</p>
    <p>There are at least seven major pathways thought to contribute to angiogenesis.</p>
    <p>The first pathway involves heparin sulfate proteoglycans (HSPG). HSPG binds basic fibroblast growth factor (bFGF), and stimulates angiogenesis in the presence of copper ions. HSPG is formed from heparin by the enzyme sulfotransferase.</p>
    <p>The second pathway involves histamine, which may stimulate angiogenesis after binding to specific histamine receptors. Histamine is formed from the amino acid histidine by the enzyme histidine decarboxylase (HDC). This synthetic reaction takes place in mast cells, and histamine is released from mast cells upon their degranulation.</p>
    <p>The third pathway involves angiotensin II, which stimulates angiogenesis after binding to angiotensin II receptors. Angiotensin II is formed from angiotensin I by angiotensin converting enzyme (ACE).</p>
    <p>The fourth pathway involves prostaglandin E1, which stimulates angiogenesis. Prostaglandin E1 synthesis is catalyzed by the enzyme prostaglandin synthase.</p>
    <p>The fifth pathway involves Substance P, an endogenous molecule that functions as a neurotransmitter and in the regulation of inflammation. Substance P also possesses angiogenic properties by acting through the neurokinin 1 receptor (NK1).</p>
    <p>The sixth pathway involves platelet activating factor (PAF), an endogenous protein that binds to a specific receptor and stimulates chemotaxis and leukocyte infiltration, which can lead to the stimulation of angiogenesis.</p>
    <p>The seventh pathway involves the arachidonic acid metabolite 12(R)-HETrE, which is angiogenic through its effects on capillary permeability, neutrophil chemotaxis, vasodilation, and endothelial cell mitogenesis. The metabolite 12(R)-HETrE is formed from 5HETE by the enzyme cytochrome P450 reductase.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>One aspect of the invention is the use of non-steroidal suppressors of angiogenesis to inhibit hair growth. It has now been found that unwanted mammalian (including human) hair growth--particularly androgen-stimulated hair growth--can be inhibited by applying to the skin a dermatologically acceptable composition including a non-steroidal suppressor of angiogenesis in an amount effective to reduce hair growth. The unwanted hair growth which is reduced may be normal hair growth, or hair growth that results from an abnormal or diseased condition.</p>
    <p>Suppressors of angiogenesis include compounds that interfere with one or more of the seven major angiogenesis pathways described previously. There are at least 12 classes of compounds that have been found to interfere with one of these pathways, and thus can be used to inhibit hair growth. The 12 classes of compounds are set forth in the Figure.</p>
    <p>Referring to the Figure, the first class of compounds inhibit the enzyme sulfotransferase. Examples include p-nitrocatechol and catechin. Inhibiting sulfotransferase interferes with the transformation of heparin to HSPG.</p>
    <p>The second class of compounds are heparin binding antagonists, which inhibit the binding of HSPG to bFGF. Examples include pentosan polysulfate and quinacrine.</p>
    <p>The third class of compounds are copper chelators, which also inhibit the binding of HSPG to bFGF. Examples include bathocuproine disulfonate and diethylenetriamine pentaacetic acid.</p>
    <p>The fourth class of compounds inhibit the enzyme HDC. Examples include O-p-nitrohydroxylamine and -fluoromethylhistidine. Inhibiting HDC interferes with the conversion of histidine to histamine.</p>
    <p>The fifth class of compounds inhibit mast cell degranulation, and this interferes with the release of histamine from mast cells. Examples include mycophenolic acid, bromocryptine, and cromoglycate.</p>
    <p>The sixth class of compounds are histamine receptor antagonists which interfere with the binding of histamine to specific histamine receptors. Examples include terfenadine, tripelennamine, chlorpheniramine, and cimetidine.</p>
    <p>The seventh class of compounds inhibit ACE. Examples include enalapril and lisinopril. Inhibiting ACE interferes with the conversion of angiotensin I to angiotensin II.</p>
    <p>The eighth class of compounds are angiotensin II receptor antagonists, which interfere with the binding of angiotensin II to specific angiotensin II receptors. Examples include 1,4-substituted indoles such as those described in Poss et al., Bioorganic &amp; Medicinal Chemistry Letters, 4:145-150 (1994); dihydropyridine derivatives like nifedipine and others described in Webster et al., Bioorganic &amp; Medicinal Chemistry Letters, 4:133-138 (1994); 2,4-dihydro-3H-1,2,4-triazol-3-ones (traizolinone) derivatives bearing a side chain at N<sup>4</sup> position as described by Chang et al. (Bioorganic &amp; Medicinal Chemistry Letters, 4:115-120 (1994)); tetrahydroisoquinoline carboxylic acids; imidazopyridine derivatives like tetrahydroimidazopyridine carboxylic acid analogs; and Losartan.</p>
    <p>The ninth class of compounds inhibit the enzyme prostaglandin synthetase. An example is piracetam. Inhibiting prostaglandin synthetase interferes with the formation of prostaglandin E1.</p>
    <p>The tenth class of compounds are NK1 receptor antagonists, which interfere with the binding of Substance P to the NK1 receptor. Examples include (3aR,7aR)-7,7,-diphenyl-2-[1-imino-2-(2-methoxyphenyl)ethyl]perhydroisoindol-4-one and cis-2-(diphenylmethyl)-N-[(2-methoxy-phenyl)]-methyl]-1-azabicyclo[2,2,2]octan-3-amine.</p>
    <p>The eleventh class of compounds are PAF receptor antagonists, which interfere with the binding of PAF to the PAF receptors. Examples include tioconazole and (3-[4-(2-chlorphenyl)-9-methyl-6H-thieno[2-f]-[1,2,4]triazolo-[4,3-a][1,4]-diazepin-2-yl-1-(4-morpholinyl)-1-propanone.</p>
    <p>The twelfth class of compounds are inhibitors of the enzyme cytochrome P450 reductase. An example is clotrimazole. Inhibiting cytochrome P450 reductase interferes with the formation of 12(R)-HETrE from 5HETE.</p>
    <p>Additional non-steroidal compounds that may inhibit angiogenesis--but which may not be members of one of the twelve classes of compounds described above--include phenyl-ethylene derivatives such as tamoxifen and nafoxidine; irsogladine; the synthetic laminin peptide, CDPGYIGSR-NH<sub>2</sub> ; radicicol; eponemycin; fumagillin (O-(chloroacetyl-carbamoyl)fumagillol) and synthetic analoges thereof; recombinant human platelet factor-4 and related peptides; protamine; sulfated chitin derivatives; diaminoanthraquinone derivatives; thrombospondin; quinoline-3-carboxamide (linomide); analogues of distamycin A; and aurintricarboxylic acid.</p>
    <p>The above compounds are known and some are commercially available.</p>
    <p>Another aspect of the invention features inhibiting mammalian hair growth by applying to the skin a dermatologically acceptable composition including an inhibitor of sulfotranferase.</p>
    <p>Another aspect of the invention features inhibiting mammalian hair growth by applying to the skin a dermatologically acceptable composition including a heparin binding antagonist.</p>
    <p>Another aspect of the invention features inhibiting mammalian hair growth by applying to the skin a dermatologically acceptable composition including a copper chelator.</p>
    <p>Another aspect of the invention features inhibiting mammalian hair growth by applying to the skin a dermatologically acceptable composition including an inhibitor of HDC.</p>
    <p>Another aspect of the invention features inhibiting mammalian hair growth by applying to the skin a dermatologically acceptable composition including an inhibitor of mast cell degranulation.</p>
    <p>Another aspect of the invention features inhibiting mammalian hair growth by applying to the skin a dermatologically acceptable composition including a histamine receptor antagonist.</p>
    <p>Another aspect of the invention features inhibiting mammalian hair growth by applying to the skin a dermatologically acceptable composition including an inhibitor of ACE.</p>
    <p>Another aspect of the invention features inhibiting mammalian hair growth by applying to the skin a dermatologically acceptable composition including an angiotensin II receptor antagonist.</p>
    <p>Another aspect of the invention features inhibiting mammalian hair growth by applying to the skin a dermatologically acceptable composition including an inhibitor of prostaglandin synthetase.</p>
    <p>Another aspect of the invention features inhibiting mammalian hair growth by applying to the skin a dermatologically acceptable composition including an NKI receptor antagonist.</p>
    <p>Another aspect of the invention features inhibiting mammalian hair growth by applying to the skin a dermatologically acceptable composition including a PAF receptor antagonist.</p>
    <p>Another aspect of the invention features inhibiting mammalian hair growth by applying to the skin a dermatologically acceptable composition including an inhibitor of cytochrome P450 reductase.</p>
    <p>Inhibitors of enzymes, and receptor antagonists, may be irreversible or reversible. Reversible inhibitors may be competitive or non-competitive.</p>
    <p>"Non-steroidal", as used herein, means a compound that lacks the 17-carbon ring structure found typically in a steroid.</p>
    <p>Other features and advantages of the invention will be apparent from the description of the embodiments thereof, and from the claim.</p>
    <heading>DRAWING</heading> <p>The FIGURE is a summary of twelve classes of compounds that interfere with angiogenesis.</p>
    <heading>EMBODIMENTS</heading> <p>The hair growth inhibiting compound is incorporated in a non-toxic dermatologically acceptable topical composition which preferably includes a vehicle or carrier which is adapted to be spread upon the skin. Examples of suitable vehicles are acetone, alcohols, or a cream, lotion, or gel which can effectively deliver the active compound. One such vehicle is disclosed in co-pending application PCT/US93/0506A. In addition, a penetration enhancer may be added to the vehicle to further enhance the effectiveness of the formulation.</p>
    <p>The concentration of the hair growth inhibiting compound in the composition may be varied over a wide range up to a saturated solution, preferably from 0.1% to 30% by weight or even more; the reduction of hair growth increases as the amount of compound applied increases per unit area of skin. The maximum amount effectively applied is limited only by the rate at which the hair growth inhibiting compound penetrates the skin. Generally, the effective amounts range from 100 to 3000 micrograms or more per square centimeter of skin.</p>
    <p>The composition should be topically applied to a selected area of the body from which it is desired to inhibit hair growth. For example, the composition can be applied to the face, particularly to the beard area of the face, i.e., the cheek, neck, upper lip, and chin. The composition can also be applied to the legs, arms, torso or armpits. The composition is particularly suitable for inhibiting the growth of unwanted hair in women suffering from hirsutism or other conditions. In humans, the composition should be applied once or twice a day, or even more frequently, for at least three months to achieve a perceived reduction in hair growth. Reduction in hair growth is demonstrated when the frequency or hair removal is reduced, or the subject perceives less hair on the treated site, or quantitatively, when the weight of hair removed by shaving (i.e., hair mass) is reduced.</p>
    <p>Male intact Golden Syrian hamsters are considered acceptable models for human beard hair growth in that they display oval shaped flank organs, one on each side, each about 8 mm in major diameter, which grow thick black and coarse hair similar to human beard hair. These organs produce hair in response to androgens in the hamster. To evaluate the effectiveness of a composition including a hair growth inhibiting compound, the flank organs of each of a group of hamsters are depilated by applying a thioglycolate based chemical depilatory (Surgex). To one organ of each animal 25 l of vehicle alone once a day is applied, while to the other organ of each animal an equal amount of vehicle containing a hair growth inhibiting compound is applied. After thirteen applications (one application per day for five days a week), the flank organs are shaved and the amount of recovered hair (hair mass) from each is weighed. Percent-reduction of hair growth is calculated by subtracting the hair mass (mg) value of the test compound treated side from the hair mass value of the vehicle treated side; the delta value obtained is then divided by the hair mass value of the vehicle treated side, and the resultant number is multiplied by 100.</p>
    <p>The above-described assay will be referred to herein as the "Golden Syrian hamster" assay. Preferred compositions provide an inhibition in hair growth of at least about 20%, more preferably at least about 40%, and most preferably at least about 60% when tested in the Golden Syrian hamster assay. A number of compositions were tested in the Golden Syrian hamster assay; the results are provided in the Table.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE__________________________________________________________________________      Hair MassCompound   Dose         Vehicle*              pH Treated(mg)                       Control(mg)                             % Inhibition__________________________________________________________________________bathocuproine      10%         A    7.0                 0.41  .06                       2.23  .20                             81  3  p-nitrocatechol sulfate 10% A 9.0 0.58  .08 2.39  .21 74  5  aurintricarboxylic acid 10% A 4.0 0.92  .08 2.70  .29 66  2  mycophenolic acid 10% D 4.0 0.60  .13 1.85  .19 65  8                              nafoxidine 10% A 5.0 0.76  .19                             1.70  .14 59  8  tamoxifen 10% A 4.5 0.72  .17 1.65  .24  56  12  catechin 10% A 4.5 0.56  .12 1.31  .12 56  8  quinacrine 10% A 6.0 1.27  .23 2.50  .40 50  8  O-p-nitrohydroxylamine 10% A 4.0 0.94  .17 1.82  .21 50  5                              diethylenetriamine 7.5%  B 4.0 1.31                              .22 2.44  .28 49  8                              pentaacetic acid  cimetidine 10% A 8.0 0.95  .14 1.85  .23 46  7  lisinopril 7.5%  A 5.0 0.79  .14 1.50  .23  44  10  piracetam 10% A 6.0 0.89  .18 1.44  .22  38  10  enalapril 10% C 5.0 1.25  .16 2.06  .11 38  9  pentosan polysulfate 10% A 6.5 1.07  .16 1.57  .12 33  7                              terfenadine  5% B 8.0 1.50  .26                             2.18  .26 32  8  tripelennamine 10% A 6.5 1.20  .23 1.80  .23 30  9  chlorfeniramine 10% A 6.0 0.92  .16 1.40  .21  29  12                              tranexamic acid 10% A 5.5 1.47                              .13 2.01  .15  21  12__________________________________________________________________________ *vehicle A = 68% H<sub>2</sub> O; 16% ethanol; 5% propylene glycol; 4% benzyl alcohol; 2% propylene carbonate B = 80% H<sub>2</sub> O; 10% dipropylene glycol; 10% ethanol C = 80% ethanol; 17.5% H<sub>2</sub> O; 2% propylene glycol dipelargonate; 0.5% propylene glycol D = 70% ethanol; 30% dimethylsulfoxamine</pre>
    
    <p>It will be appreciated by those skilled in the art that the invention can be performed within a wide range of equivalent parameters of composition and conditions without departing from the spirit or scope of the invention or of any embodiment thereof.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3426137">US3426137</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 23, 1965</td><td class="patent-data-table-td patent-date-value">Feb 4, 1969</td><td class="patent-data-table-td ">Olin Mathieson</td><td class="patent-data-table-td ">Hair growth inhibiting by aminobenzophenones</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4039669">US4039669</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 1, 1975</td><td class="patent-data-table-td patent-date-value">Aug 2, 1977</td><td class="patent-data-table-td ">Sterling Drug Inc.</td><td class="patent-data-table-td ">Composition for topical application and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4139638">US4139638</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 3, 1977</td><td class="patent-data-table-td patent-date-value">Feb 13, 1979</td><td class="patent-data-table-td ">Schering Corporation</td><td class="patent-data-table-td ">Methods for the treatment of hirsutism</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4161540">US4161540</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 3, 1977</td><td class="patent-data-table-td patent-date-value">Jul 17, 1979</td><td class="patent-data-table-td ">Schering Corporation</td><td class="patent-data-table-td ">Antiandrogenic agents and methods for the treatment of androgen dependent disease states</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4191775">US4191775</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 29, 1978</td><td class="patent-data-table-td patent-date-value">Mar 4, 1980</td><td class="patent-data-table-td ">Imperial Chemical Industries Limited</td><td class="patent-data-table-td ">Amide derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4269831">US4269831</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 9, 1979</td><td class="patent-data-table-td patent-date-value">May 26, 1981</td><td class="patent-data-table-td ">Sterling Drug Inc.</td><td class="patent-data-table-td ">Topical dermatological method of use of an androstenopyrazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4344941">US4344941</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 20, 1980</td><td class="patent-data-table-td patent-date-value">Aug 17, 1982</td><td class="patent-data-table-td ">Schering Aktiengesellschaft (A.G.)</td><td class="patent-data-table-td ">Antiandrogenic 17-substituted steroids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4370315">US4370315</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 22, 1978</td><td class="patent-data-table-td patent-date-value">Jan 25, 1983</td><td class="patent-data-table-td ">Sederma</td><td class="patent-data-table-td ">Lipoxygenase, linoleic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4439432">US4439432</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 22, 1982</td><td class="patent-data-table-td patent-date-value">Mar 27, 1984</td><td class="patent-data-table-td ">Peat Raymond F</td><td class="patent-data-table-td ">Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4720489">US4720489</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 15, 1984</td><td class="patent-data-table-td patent-date-value">Jan 19, 1988</td><td class="patent-data-table-td ">Douglas Shander</td><td class="patent-data-table-td ">Hair growth modification with ornithine decarboxylase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4885289">US4885289</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 11, 1985</td><td class="patent-data-table-td patent-date-value">Dec 5, 1989</td><td class="patent-data-table-td ">Breuer Miklos M</td><td class="patent-data-table-td ">Alteration of character of male beard growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5095007">US5095007</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 24, 1990</td><td class="patent-data-table-td patent-date-value">Mar 10, 1992</td><td class="patent-data-table-td ">Ahluwalia Gurpreet S</td><td class="patent-data-table-td ">Enzyme inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5096911">US5096911</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 25, 1990</td><td class="patent-data-table-td patent-date-value">Mar 17, 1992</td><td class="patent-data-table-td ">Ahluwalia Gurpreet S</td><td class="patent-data-table-td ">Alteration of rate and character of hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5132293">US5132293</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 28, 1991</td><td class="patent-data-table-td patent-date-value">Jul 21, 1992</td><td class="patent-data-table-td ">Douglas Shander</td><td class="patent-data-table-td ">Enzyme inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5143925">US5143925</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 12, 1991</td><td class="patent-data-table-td patent-date-value">Sep 1, 1992</td><td class="patent-data-table-td ">Douglas Shander</td><td class="patent-data-table-td ">Alteration of rate and character of hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5189212">US5189212</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 7, 1990</td><td class="patent-data-table-td patent-date-value">Feb 23, 1993</td><td class="patent-data-table-td ">University Of Georgia Research Foundation, Inc.</td><td class="patent-data-table-td ">Used in estrogen replacement therapy like menopause, osteoporosis therapy, prevention of excessive hair growth of body and infertility</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5271942">US5271942</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 25, 1991</td><td class="patent-data-table-td patent-date-value">Dec 21, 1993</td><td class="patent-data-table-td ">Ulrich Heverhagen</td><td class="patent-data-table-td ">Agent for reducing the growth of or removing the hair on the human body</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5300284">US5300284</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 28, 1992</td><td class="patent-data-table-td patent-date-value">Apr 5, 1994</td><td class="patent-data-table-td ">Chesebrough-Pond&#39;s Usa Co., Division Of Conopco, Inc.</td><td class="patent-data-table-td ">Breaking the hydrogen bonding between sugar-like molecules to prevent stickiness and stiffness</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5364885">US5364885</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 13, 1992</td><td class="patent-data-table-td patent-date-value">Nov 15, 1994</td><td class="patent-data-table-td ">Ahluwalia Gurpreet S</td><td class="patent-data-table-td ">Reduction of hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5378455">US5378455</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 27, 1993</td><td class="patent-data-table-td patent-date-value">Jan 3, 1995</td><td class="patent-data-table-td ">Chesebrough-Ponds Usa Co., Division Of Conopco, Inc.</td><td class="patent-data-table-td ">Cosmetic composition for inhibiting hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5407944">US5407944</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 19, 1993</td><td class="patent-data-table-td patent-date-value">Apr 18, 1995</td><td class="patent-data-table-td ">Goldman; Boris E.</td><td class="patent-data-table-td ">Compositions and methods for promoting hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5554608">US5554608</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 28, 1994</td><td class="patent-data-table-td patent-date-value">Sep 10, 1996</td><td class="patent-data-table-td ">Ahluwalia; Gurpreet S.</td><td class="patent-data-table-td ">Inhibition of hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5753612">US5753612</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 7, 1995</td><td class="patent-data-table-td patent-date-value">May 19, 1998</td><td class="patent-data-table-td ">Yissum Research Development Co. Of The Hebrew University Of Jerusalem</td><td class="patent-data-table-td ">Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0413528A1?cl=en">EP0413528A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 10, 1990</td><td class="patent-data-table-td patent-date-value">Feb 20, 1991</td><td class="patent-data-table-td ">Ruey J. Dr. Yu</td><td class="patent-data-table-td ">Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0532219A2?cl=en">EP0532219A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 2, 1992</td><td class="patent-data-table-td patent-date-value">Mar 17, 1993</td><td class="patent-data-table-td ">Unilever Plc</td><td class="patent-data-table-td ">Cosmetic composition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=T2pQBAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DFR%26NR%3D2753375A1%26KC%3DA1%26FT%3DD&amp;usg=AFQjCNEB-VQANNPF_WKNMNo4XbDFEMAxUw">FR2753375A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=T2pQBAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DGB%26NR%3D1458349A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNGwqPd5qxw0RKjknubhHGMmJoxGeQ">GB1458349A</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=T2pQBAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DJP%26NR%3DH07112923A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNFcXLWzFjFaLGvLr3MrQENqgxaI5g">JPH07112923A</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1990012577A2?cl=en">WO1990012577A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 20, 1990</td><td class="patent-data-table-td patent-date-value">Nov 1, 1990</td><td class="patent-data-table-td ">Upjohn Co</td><td class="patent-data-table-td ">Topical anti-angiogenic as hair growth inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994004143A1?cl=en">WO1994004143A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 17, 1993</td><td class="patent-data-table-td patent-date-value">Mar 3, 1994</td><td class="patent-data-table-td ">Alcon Lab Inc</td><td class="patent-data-table-td ">Substituted hydrindanes for the treatment of angiogenesis-dependent diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994027563A1?cl=en">WO1994027563A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 16, 1994</td><td class="patent-data-table-td patent-date-value">Dec 8, 1994</td><td class="patent-data-table-td ">Gurpreet S Ahluwalia</td><td class="patent-data-table-td ">Inhibition of hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994027586A1?cl=en">WO1994027586A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 16, 1994</td><td class="patent-data-table-td patent-date-value">Dec 8, 1994</td><td class="patent-data-table-td ">Gurpreet S Ahluwalia</td><td class="patent-data-table-td ">Inhibition of hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1997041844A1?cl=en">WO1997041844A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 3, 1997</td><td class="patent-data-table-td patent-date-value">Nov 13, 1997</td><td class="patent-data-table-td ">Alcon Lab Inc</td><td class="patent-data-table-td ">Combinations of angiostatic compounds</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ahluwalia, "<a href='http://scholar.google.com/scholar?q="Method+of+Reducing+the+Rate+of+Hair+Growth"'>Method of Reducing the Rate of Hair Growth</a>", U.S.S.N. 08/212,584, allowed.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ahluwalia, Method of Reducing the Rate of Hair Growth , U.S.S.N. 08/212,584, allowed.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Alluwalia et al., "<a href='http://scholar.google.com/scholar?q="Inhibition+of+Hair+Growth"'>Inhibition of Hair Growth</a>", U.S.S.N. 08/213,954, allowed.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Alluwalia et al., Inhibition of Hair Growth , U.S.S.N. 08/213,954, allowed.</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Arias et al., "<a href='http://scholar.google.com/scholar?q="Effects+of+Cyproterone+and+Tamoxifen+Upon+the+Hair+Waves+in+Mice"'>Effects of Cyproterone and Tamoxifen Upon the Hair Waves in Mice</a>", Chemical Abstracts, 99:101, 1083, see abstract; ACTA Physiol. Latinoam., 32:261-266, 1982.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Arias et al., Effects of Cyproterone and Tamoxifen Upon the Hair Waves in Mice , Chemical Abstracts, 99:101, 1083, see abstract; ACTA Physiol. Latinoam., 32:261 266, 1982.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Borgstr o m et al., The quinoline 3 carboxamide Linomide inhibits angiogenesis in vivo , Cancer Chemotherapy and Pharmacology , 34:280 286 (1994).</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Borgstrom et al., "<a href='http://scholar.google.com/scholar?q="The+quinoline-3-carboxamide+Linomide+inhibits+angiogenesis+in+vivo"'>The quinoline-3-carboxamide Linomide inhibits angiogenesis in vivo</a>", Cancer Chemotherapy and Pharmacology, 34:280-286 (1994).</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Burdick et al., "<a href='http://scholar.google.com/scholar?q="The+Topical+Effect+of+the+Antiandrogen+Chlormadin--One+Acetate+and+Some+of+its+.+.+.+"'>The Topical Effect of the Antiandrogen Chlormadin--One Acetate and Some of its . . . </a>", Br. J. Derm., 82:19-25 Supplemetn 6, 19 (1970).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Burdick et al., The Topical Effect of the Antiandrogen Chlormadin One Acetate and Some of its . . . , Br. J. Derm. , 82:19 25 Supplemetn 6, 19 (1970).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">CA113(15):126168f of Hear. Res. 46(1 2), 101 12 (1990).</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">CA113(15):126168f of Hear. Res. 46(1-2), 101-12 (1990).</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chang et al., "<a href='http://scholar.google.com/scholar?q="Triazolinones+as+Nonpeptide+Angiotensin+II+Antagonists.+2.+Discovery+of+a+Potent+and+.+.+.+"'>Triazolinones as Nonpeptide Angiotensin II Antagonists. 2. Discovery of a Potent and . . . </a>", Bioorganic &amp; Medicinal Chemistry Letters, 4:115-120 (1994).</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Chang et al., Triazolinones as Nonpeptide Angiotensin II Antagonists. 2. Discovery of a Potent and . . . , Bioorganic &amp; Medicinal Chemistry Letters , 4:115 120 (1994).</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Cohen, "<a href='http://scholar.google.com/scholar?q="A+platelet-activating+factor+antagonist+reduces+corneal+allograft+inflammation+and+neovascularization"'>A platelet-activating factor antagonist reduces corneal allograft inflammation and neovascularization</a>", Current Eye Research, 13:139-144 (1994).</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Cohen, A platelet activating factor antagonist reduces corneal allograft inflammation and neovascularization , Current Eye Research , 13:139 144 (1994).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fan et al., "<a href='http://scholar.google.com/scholar?q="Stimulation+of+angiogenesis+by+substance+P+and+interleukin-1+in+the+rat+and+its+inhibition+.+.+.+"'>Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition . . . </a>", Br. J. Pharmacol., 110:43-49 (1993).</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Fan et al., Stimulation of angiogenesis by substance P and interleukin 1 in the rat and its inhibition . . . , Br. J. Pharmacol. , 110:43 49 (1993).</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Folkman et al., "<a href='http://scholar.google.com/scholar?q="Minireview%3A+Angiogenesis"'>Minireview: Angiogenesis</a>", The Journal of Biological Chemistry, 267:10931-10934 (1992).</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Folkman et al., Minireview: Angiogenesis , The Journal of Biological Chemistry , 267:10931 10934 (1992).</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Golditch et al. Treatment of Hirsutism with Cimetidine. Obstetrics &amp; Gynecology, vol. 75, No. 6, pp. 911 913. Jun. 1990.</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Golditch et al. Treatment of Hirsutism with Cimetidine. Obstetrics &amp; Gynecology, vol. 75, No. 6, pp. 911-913. Jun. 1990.</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Goos et al., "<a href='http://scholar.google.com/scholar?q="An+Improved+Method+for+Evaluating+Antiandrogens"'>An Improved Method for Evaluating Antiandrogens</a>", Arch. Dermatol. Res., 273:333-341 (1982).</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Goos et al., An Improved Method for Evaluating Antiandrogens , Arch. Dermatol. Res. , 273:333 341 (1982).</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Gullino, "<a href='http://scholar.google.com/scholar?q="Considerations+on+the+Mechanism+of+the+Angiogenic+Response"'>Considerations on the Mechanism of the Angiogenic Response</a>", Anticancer Research, 6:153-158 (1986).</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Gullino, Considerations on the Mechanism of the Angiogenic Response , Anticancer Research , 6:153 158 (1986).</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Harmon et al., "<a href='http://scholar.google.com/scholar?q="12-O-Tetradecanoylphorbol-13-Acetate+Inhibits+Human+Hair+Follicle+Growth+and+Hair+Fiber+Production+in+Whole-Organ+Cultures"'>12-O-Tetradecanoylphorbol-13-Acetate Inhibits Human Hair Follicle Growth and Hair Fiber Production in Whole-Organ Cultures</a>", SID Abstracts, 102:533 (Apr., 1994).</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Harmon et al., 12 O Tetradecanoylphorbol 13 Acetate Inhibits Human Hair Follicle Growth and Hair Fiber Production in Whole Organ Cultures , SID Abstracts , 102:533 (Apr., 1994).</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Laniado Schwartzman et al., Activation Nuclear Factor kB and Oncogene Expression by 12(R) Hydroxyeicosatrienoic Acid . . . , The Journal of Biological Chemistry , 269:24321 24327 (1994).</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Laniado-Schwartzman et al., "<a href='http://scholar.google.com/scholar?q="Activation+Nuclear+Factor+kB+and+Oncogene+Expression+by+12%28R%29-Hydroxyeicosatrienoic+Acid+.+.+.+"'>Activation Nuclear Factor kB and Oncogene Expression by 12(R)-Hydroxyeicosatrienoic Acid . . . </a>", The Journal of Biological Chemistry, 269:24321-24327 (1994).</td></tr><tr><td class="patent-data-table-td ">31</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Le Noble et al., "<a href='http://scholar.google.com/scholar?q="Angiotensin+II+stimulates+angiogenesis+in+the+chorio-allantoic+membrane+of+the+chick+embryo"'>Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo</a>", European Journal of Pharmacology, 195:305-306 (1991).</td></tr><tr><td class="patent-data-table-td ">32</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Le Noble et al., Angiotensin II stimulates angiogenesis in the chorio allantoic membrane of the chick embryo , European Journal of Pharmacology , 195:305 306 (1991).</td></tr><tr><td class="patent-data-table-td ">33</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Li et al., "<a href='http://scholar.google.com/scholar?q="Diminished+Heparin+Binding+of+a+Basic+Fibroblast+Growth+Factor+Mutant+Is+Associated+with+.+.+.+"'>Diminished Heparin Binding of a Basic Fibroblast Growth Factor Mutant Is Associated with . . . </a>", Biochemistry, 33:10999-11007 (1994).</td></tr><tr><td class="patent-data-table-td ">34</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Li et al., Diminished Heparin Binding of a Basic Fibroblast Growth Factor Mutant Is Associated with . . . , Biochemistry , 33:10999 11007 (1994).</td></tr><tr><td class="patent-data-table-td ">35</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Lissak et al. Treatment of Hirsutism with Cimetidine: A Prospective Randomized Controlled Trial. Fertil Steril. vol. 51, No. 2, pp. 247 250. Feb. 1989.</td></tr><tr><td class="patent-data-table-td ">36</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lissak et al. Treatment of Hirsutism with Cimetidine: A Prospective Randomized Controlled Trial. Fertil-Steril. vol. 51, No. 2, pp. 247-250. Feb. 1989.</td></tr><tr><td class="patent-data-table-td ">37</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Majewski et al., "<a href='http://scholar.google.com/scholar?q="Relationship+Between+the+Hair+Growth+Cycle+and+the+Intensity+of+Lymphocyte-Induced+Angiogenesis+in+Mouse+Skin"'>Relationship Between the Hair Growth Cycle and the Intensity of Lymphocyte-Induced Angiogenesis in Mouse Skin</a>", 277:77-78, 1985.</td></tr><tr><td class="patent-data-table-td ">38</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Majewski et al., Relationship Between the Hair Growth Cycle and the Intensity of Lymphocyte Induced Angiogenesis in Mouse Skin , 277:77 78, 1985.</td></tr><tr><td class="patent-data-table-td ">39</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Messenger, "<a href='http://scholar.google.com/scholar?q="The+Control+of+Hair+Growth%3A+An+Overview"'>The Control of Hair Growth: An Overview</a>", Journal of Investigative Dermatology, 101:4S-9S (Jul., 1993).</td></tr><tr><td class="patent-data-table-td ">40</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Messenger, The Control of Hair Growth: An Overview , Journal of Investigative Dermatology , 101:4S 9S (Jul., 1993).</td></tr><tr><td class="patent-data-table-td ">41</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nguyen et al., "<a href='http://scholar.google.com/scholar?q="Pentosan+Inhibits+Angiogenesis+In+Vitro+and+Suppresses+Prostate+Tumor+Growth+In+Vivo"'>Pentosan Inhibits Angiogenesis In Vitro and Suppresses Prostate Tumor Growth In Vivo</a>", Chemical Abstracts, 120:35, 1994, see abstract; Anticancer Research, 13:2143-2147, 1993.</td></tr><tr><td class="patent-data-table-td ">42</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Nguyen et al., Pentosan Inhibits Angiogenesis In Vitro and Suppresses Prostate Tumor Growth In Vivo , Chemical Abstracts, 120:35, 1994, see abstract; Anticancer Research, 13:2143 2147, 1993.</td></tr><tr><td class="patent-data-table-td ">43</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Notification of Transmittal of The International Search Report or the Declaration (8 pages).</td></tr><tr><td class="patent-data-table-td ">44</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Paus, "<a href='http://scholar.google.com/scholar?q="Hair+Grwoth+Inhibition+by+Heparin+in+Mice%3A+A+Model+System+for+Studying+the+Modulation+of+Epithelial+Cell+Growth+by+Glucosaminoglycans%3F"'>Hair Grwoth Inhibition by Heparin in Mice: A Model System for Studying the Modulation of Epithelial Cell Growth by Glucosaminoglycans?</a>", British Journal of Dermatology, 124:415-422, 1991.</td></tr><tr><td class="patent-data-table-td ">45</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Paus, Hair Grwoth Inhibition by Heparin in Mice: A Model System for Studying the Modulation of Epithelial Cell Growth by Glucosaminoglycans , British Journal of Dermatology, 124:415 422, 1991.</td></tr><tr><td class="patent-data-table-td ">46</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Poss et al., "<a href='http://scholar.google.com/scholar?q="1%2C4-Substituted+Indoles%3A+A+Potent+and+Selective+Class+of+Angiotensin+II+Receptor+Antagonists"'>1,4-Substituted Indoles: A Potent and Selective Class of Angiotensin II Receptor Antagonists</a>", Bioorganic &amp; Medicinal Chemistry Letters, 4:145-150 (1994).</td></tr><tr><td class="patent-data-table-td ">47</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Poss et al., 1,4 Substituted Indoles: A Potent and Selective Class of Angiotensin II Receptor Antagonists , Bioorganic &amp; Medicinal Chemistry Letters , 4:145 150 (1994).</td></tr><tr><td class="patent-data-table-td ">48</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Raju et al., "<a href='http://scholar.google.com/scholar?q="Ceruloplasmin%2C+Copper+Ions%2C+and+Angiogenesis1%2C2+"'>Ceruloplasmin, Copper Ions, and Angiogenesis1,2 </a>", JNCI, 69:1183-1188.</td></tr><tr><td class="patent-data-table-td ">49</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Raju et al., Ceruloplasmin, Copper Ions, and Angiogenesis 1,2 , JNCI , 69:1183 1188.</td></tr><tr><td class="patent-data-table-td ">50</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sato, "<a href='http://scholar.google.com/scholar?q="The+Hair+Cycle+and+its+Control+Mechanism"'>The Hair Cycle and its Control Mechanism</a>", Biology and Disease of the Hair, 3-13 (1975).</td></tr><tr><td class="patent-data-table-td ">51</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Sato, The Hair Cycle and its Control Mechanism , Biology and Disease of the Hair , 3 13 (1975).</td></tr><tr><td class="patent-data-table-td ">52</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Shander et al., "<a href='http://scholar.google.com/scholar?q="Method+of+Reducing+Hair+Growth+Employing+Sulfhydryl+Active+Compounds"'>Method of Reducing Hair Growth Employing Sulfhydryl Active Compounds</a>", U.S. Patent No. 5,411,991, issued May 2, 1995.</td></tr><tr><td class="patent-data-table-td ">53</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Shander et al., Method of Reducing Hair Growth Employing Sulfhydryl Active Compounds , U.S. Patent No. 5,411,991, issued May 2, 1995.</td></tr><tr><td class="patent-data-table-td ">54</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Siegl et al., "<a href='http://scholar.google.com/scholar?q="In+Vivo+Pharmacology+of+L-158%2C809%2C+a+New+Highly+Potent+and+Selective+Nonpeptide+.+.+.+"'>In Vivo Pharmacology of L-158,809, a New Highly Potent and Selective Nonpeptide . . . </a>", The Journal of Pharmacology and Experimental Therapeutics, 262:139-144 (1992).</td></tr><tr><td class="patent-data-table-td ">55</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Siegl et al., In Vivo Pharmacology of L 158,809, a New Highly Potent and Selective Nonpeptide . . . , The Journal of Pharmacology and Experimental Therapeutics , 262:139 144 (1992).</td></tr><tr><td class="patent-data-table-td ">56</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Simpson et al., "<a href='http://scholar.google.com/scholar?q="The+effect+of+topically+applied+progesterone+on+sebum+excretion+rate"'>The effect of topically applied progesterone on sebum excretion rate</a>", British Journal, of Dermatology, 100:687-692 (1979).</td></tr><tr><td class="patent-data-table-td ">57</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Simpson et al., The effect of topically applied progesterone on sebum excretion rate , British Journal, of Dermatology , 100:687 692 (1979).</td></tr><tr><td class="patent-data-table-td ">58</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sorbo et al., "<a href='http://scholar.google.com/scholar?q="Mast-cell+histamine+is+angiogenic+through+receptors+for+histamine1+and+histamine2+"'>Mast-cell histamine is angiogenic through receptors for histamine1 and histamine2 </a>", Int. J. Exp. Path., 75:43-50 (1994).</td></tr><tr><td class="patent-data-table-td ">59</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Sorbo et al., Mast cell histamine is angiogenic through receptors for histamine 1 and histamine 2 , Int. J. Exp. Path. , 75:43 50 (1994).</td></tr><tr><td class="patent-data-table-td ">60</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Takano et al., "<a href='http://scholar.google.com/scholar?q="A+Diaminoanthraquinone+Inhibitor+of+Angiogenesis"'>A Diaminoanthraquinone Inhibitor of Angiogenesis</a>", The Journal of Pharmacology and Experimental Therapeutics, 271:1027-1033 (1994).</td></tr><tr><td class="patent-data-table-td ">61</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Takano et al., A Diaminoanthraquinone Inhibitor of Angiogenesis , The Journal of Pharmacology and Experimental Therapeutics , 271:1027 1033 (1994).</td></tr><tr><td class="patent-data-table-td ">62</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ushmorov et al., "<a href='http://scholar.google.com/scholar?q="Effects+of+Complete+and+Imcomplete+Tumor+Promoters+on+Hair+Growth%2C+Angiogenesis%2C+and+Tenascin+Expression+in+the+Skin+of+NMRI+Mice"'>Effects of Complete and Imcomplete Tumor Promoters on Hair Growth, Angiogenesis, and Tenascin Expression in the Skin of NMRI Mice</a>", Carcinogenesis, 15:2739-2745, 1994.</td></tr><tr><td class="patent-data-table-td ">63</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ushmorov et al., Effects of Complete and Imcomplete Tumor Promoters on Hair Growth, Angiogenesis, and Tenascin Expression in the Skin of NMRI Mice , Carcinogenesis, 15:2739 2745, 1994.</td></tr><tr><td class="patent-data-table-td ">64</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wester et al., "<a href='http://scholar.google.com/scholar?q="Dihydropyridines%3A+A+New+Class+of+Angiotensin+II+Antagonists"'>Dihydropyridines: A New Class of Angiotensin II Antagonists</a>", Bioorganic &amp; Medicinal Chemistry Letters, 4:133-138 (1994).</td></tr><tr><td class="patent-data-table-td ">65</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Wester et al., Dihydropyridines: A New Class of Angiotensin II Antagonists , Bioorganic &amp; Medicinal Chemistry Letters , 4:133 138 (1994).</td></tr><tr><td class="patent-data-table-td ">66</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Westgate et al., "<a href='http://scholar.google.com/scholar?q="Distribution+of+Proteoglycans+During+the+Hair+Growth+Cycle+in+Human+Skin"'>Distribution of Proteoglycans During the Hair Growth Cycle in Human Skin</a>", The J. of Investigative Dermatology, 96:191-195, 1991.</td></tr><tr><td class="patent-data-table-td ">67</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Westgate et al., Distribution of Proteoglycans During the Hair Growth Cycle in Human Skin , The J. of Investigative Dermatology, 96:191 195, 1991.</td></tr><tr><td class="patent-data-table-td ">68</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ziche et al., "<a href='http://scholar.google.com/scholar?q="Role+of+Prostaglandin+E1+and+Copper+in+Angiogenesis1%2C2+"'>Role of Prostaglandin E1 and Copper in Angiogenesis1,2 </a>", JNCI, 69:475-480 (1982).</td></tr><tr><td class="patent-data-table-td ">69</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ziche et al., Role of Prostaglandin E 1 and Copper in Angiogenesis 1,2 , JNCI , 69:475 480 (1982).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6299865">US6299865</a></td><td class="patent-data-table-td patent-date-value">May 2, 2000</td><td class="patent-data-table-td patent-date-value">Oct 9, 2001</td><td class="patent-data-table-td ">Peter Styczynski</td><td class="patent-data-table-td ">Selecting area of skin; applying alkaline phosphatase inhibitor other than cromoglycate or its salt to reduce hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6743822">US6743822</a></td><td class="patent-data-table-td patent-date-value">Jul 17, 2002</td><td class="patent-data-table-td patent-date-value">Jun 1, 2004</td><td class="patent-data-table-td ">The Gillette Company</td><td class="patent-data-table-td ">Applying to area of skin a dermatologically acceptable composition comprising alpha -difluoromethylornithine in an amount effective to reduce hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6747017">US6747017</a></td><td class="patent-data-table-td patent-date-value">Dec 28, 1998</td><td class="patent-data-table-td patent-date-value">Jun 8, 2004</td><td class="patent-data-table-td ">Kao Corporation</td><td class="patent-data-table-td ">Endopeptidase inhibitor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7015349">US7015349</a></td><td class="patent-data-table-td patent-date-value">Mar 26, 2003</td><td class="patent-data-table-td patent-date-value">Mar 21, 2006</td><td class="patent-data-table-td ">The Gillette Company</td><td class="patent-data-table-td ">A conjugate of alpha -difluoromethylornithine can be applied topically to reduce hair growth from the area of skin in on the face, legs or underarm</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7160921">US7160921</a></td><td class="patent-data-table-td patent-date-value">Aug 7, 2003</td><td class="patent-data-table-td patent-date-value">Jan 9, 2007</td><td class="patent-data-table-td ">The Gillette Company</td><td class="patent-data-table-td ">Reduction of hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7223562">US7223562</a></td><td class="patent-data-table-td patent-date-value">Mar 31, 2005</td><td class="patent-data-table-td patent-date-value">May 29, 2007</td><td class="patent-data-table-td ">New York University</td><td class="patent-data-table-td ">Nucleic acid and amino acid sequences of FP-1 protein expressed in follicular papilla of hair follicle; antibodies; transformation, genetic engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7261878">US7261878</a></td><td class="patent-data-table-td patent-date-value">Jul 17, 2002</td><td class="patent-data-table-td patent-date-value">Aug 28, 2007</td><td class="patent-data-table-td ">The Gillette Company</td><td class="patent-data-table-td ">Reduction of hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7345192">US7345192</a></td><td class="patent-data-table-td patent-date-value">Nov 10, 2005</td><td class="patent-data-table-td patent-date-value">Mar 18, 2008</td><td class="patent-data-table-td ">The Gillette Company</td><td class="patent-data-table-td ">Reduction of hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7413751">US7413751</a></td><td class="patent-data-table-td patent-date-value">Oct 25, 2002</td><td class="patent-data-table-td patent-date-value">Aug 19, 2008</td><td class="patent-data-table-td ">Depomed, Inc.</td><td class="patent-data-table-td ">Methods of treatment using a gastric retained losartan dosage</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7420038">US7420038</a></td><td class="patent-data-table-td patent-date-value">Feb 21, 2007</td><td class="patent-data-table-td patent-date-value">Sep 2, 2008</td><td class="patent-data-table-td ">New York University</td><td class="patent-data-table-td ">Compositions for controlling hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7439271">US7439271</a></td><td class="patent-data-table-td patent-date-value">Jun 27, 2001</td><td class="patent-data-table-td patent-date-value">Oct 21, 2008</td><td class="patent-data-table-td ">The Gillette Company</td><td class="patent-data-table-td ">Reduction of hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7468421">US7468421</a></td><td class="patent-data-table-td patent-date-value">Jan 3, 2005</td><td class="patent-data-table-td patent-date-value">Dec 23, 2008</td><td class="patent-data-table-td ">Kao Corporation</td><td class="patent-data-table-td ">Administering andothelins, or antagonist thereof, as drug or cosmetics for hair removal or wool harvesting</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7618956">US7618956</a></td><td class="patent-data-table-td patent-date-value">May 31, 2005</td><td class="patent-data-table-td patent-date-value">Nov 17, 2009</td><td class="patent-data-table-td ">The Gillette Company</td><td class="patent-data-table-td ">Reduction of hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7705126">US7705126</a></td><td class="patent-data-table-td patent-date-value">Aug 7, 2008</td><td class="patent-data-table-td patent-date-value">Apr 27, 2010</td><td class="patent-data-table-td ">New York University</td><td class="patent-data-table-td ">Compositions for controlling hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7727516">US7727516</a></td><td class="patent-data-table-td patent-date-value">Feb 22, 2007</td><td class="patent-data-table-td patent-date-value">Jun 1, 2010</td><td class="patent-data-table-td ">The Procter &amp; Gamble Company</td><td class="patent-data-table-td ">Reduction of hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7772181">US7772181</a></td><td class="patent-data-table-td patent-date-value">Oct 15, 2008</td><td class="patent-data-table-td patent-date-value">Aug 10, 2010</td><td class="patent-data-table-td ">Danisco Us Inc.</td><td class="patent-data-table-td ">that target cytokines; greater activity; produced at greater yields; second protease inhibitory loop of BBPI scaffold is replaced with a binding peptide: VEGF binding peptide, fibroblast growth factor-5 (FGF) binding peptide, transforming growth factor beta (TGF) binding peptide, or TNF binding protein</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7803902">US7803902</a></td><td class="patent-data-table-td patent-date-value">Oct 15, 2008</td><td class="patent-data-table-td patent-date-value">Sep 28, 2010</td><td class="patent-data-table-td ">Danisco Us Inc.</td><td class="patent-data-table-td ">comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs; has a greater trypsin inhibitory activity; used in personal care</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7947475">US7947475</a></td><td class="patent-data-table-td patent-date-value">May 13, 2010</td><td class="patent-data-table-td patent-date-value">May 24, 2011</td><td class="patent-data-table-td ">Danisco Us Inc.</td><td class="patent-data-table-td ">comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs; has a greater trypsin inhibitory activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8282946">US8282946</a></td><td class="patent-data-table-td patent-date-value">Oct 11, 2005</td><td class="patent-data-table-td patent-date-value">Oct 9, 2012</td><td class="patent-data-table-td ">Kao Corporaion</td><td class="patent-data-table-td ">Water-soluble ginger root extract</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8394941">US8394941</a></td><td class="patent-data-table-td patent-date-value">Apr 8, 2011</td><td class="patent-data-table-td patent-date-value">Mar 12, 2013</td><td class="patent-data-table-td ">Danisco Us Inc.</td><td class="patent-data-table-td ">Modified variant Bowman Birk Protease Inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8551462">US8551462</a></td><td class="patent-data-table-td patent-date-value">May 25, 2010</td><td class="patent-data-table-td patent-date-value">Oct 8, 2013</td><td class="patent-data-table-td ">Elc Management, Llc</td><td class="patent-data-table-td ">Cosmetic composition and method for retarding hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2581080A1?cl=en">EP2581080A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 13, 2011</td><td class="patent-data-table-td patent-date-value">Apr 17, 2013</td><td class="patent-data-table-td ">Helmholtz-Zentrum fr Infektionsforschung GmbH</td><td class="patent-data-table-td ">Inhibitor of colonisation of mucosa</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005051335A1?cl=en">WO2005051335A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 24, 2004</td><td class="patent-data-table-td patent-date-value">Jun 9, 2005</td><td class="patent-data-table-td ">Gurpreet S Ahluwalia</td><td class="patent-data-table-td ">Reduction of hair growth by applying an agonist of prostaglandin dp-receptor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013053881A1?cl=en">WO2013053881A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 12, 2012</td><td class="patent-data-table-td patent-date-value">Apr 18, 2013</td><td class="patent-data-table-td ">Helmholtz-Zentrum fr Infektionsforschung GmbH</td><td class="patent-data-table-td ">Inhibitor of colonisation of mucosa</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S183000">514/183</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S874000">514/874</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S250000">514/250</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S220000">514/220</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S844000">514/844</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S074000">424/74</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S020700">514/20.7</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008000000">A61K8/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008368000">A61K8/368</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0207270000">C07D207/27</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031403500">A61K31/4035</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0233640000">C07D233/64</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031403000">A61K31/403</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031195000">A61K31/195</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008440000">A61K8/44</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008360000">A61K8/36</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031415000">A61K31/415</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008460000">A61K8/46</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008410000">A61K8/41</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0207160000">C07D207/16</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0307860000">C07D307/86</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008490000">A61K8/49</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031353000">A61K31/353</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0211220000">C07D211/22</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61Q0005000000">A61Q5/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031435000">A61K31/435</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031350000">A61K31/35</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031400000">A61K31/40</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031445000">A61K31/445</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008200000">A61K8/20</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031401500">A61K31/4015</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008640000">A61K8/64</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008330000">A61K8/33</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0209440000">C07D209/44</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008730000">A61K8/73</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031352000">A61K31/352</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031340000">A61K31/34</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031470000">A61K31/47</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008660000">A61K8/66</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031135000">A61K31/135</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008990000">A61K8/99</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61Q0007020000">A61Q7/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0311620000">C07D311/62</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031343000">A61K31/343</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031451000">A61K31/451</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0043000000">A61P43/00</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=Y10S514/844">Y10S514/844</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=Y10S514/874">Y10S514/874</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K8/4913">A61K8/4913</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K8/44">A61K8/44</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K8/4946">A61K8/4946</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K8/368">A61K8/368</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61Q7/02">A61Q7/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K8/4973">A61K8/4973</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K8/735">A61K8/735</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K8/4926">A61K8/4926</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K8/498">A61K8/498</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K2800/51">A61K2800/51</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K8/66">A61K8/66</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K8/49">A61K8/49</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K8/41">A61K8/41</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K8/492">A61K8/492</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=T2pQBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K8/64">A61K8/64</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K8/41</span>, <span class="nested-value">A61K8/44</span>, <span class="nested-value">A61K8/49F1</span>, <span class="nested-value">A61K8/49C2</span>, <span class="nested-value">A61K8/49H</span>, <span class="nested-value">A61K8/73L</span>, <span class="nested-value">A61K8/49H2</span>, <span class="nested-value">A61K8/49C2C</span>, <span class="nested-value">A61K8/49</span>, <span class="nested-value">A61K8/368</span>, <span class="nested-value">A61K8/64</span>, <span class="nested-value">A61K8/49C4</span>, <span class="nested-value">A61Q7/02</span>, <span class="nested-value">A61K8/66</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Sep 23, 2011</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 22, 2009</td><td class="patent-data-table-td ">FPB1</td><td class="patent-data-table-td ">Expired due to reexamination which canceled all claims</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 22, 2008</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20080523</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 4, 2008</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 26, 2004</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U2ELubsqjZjSwbW9SSU47ue49Jk4g\u0026id=T2pQBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U1Pua94ouwbrI6I2KdsnUTz1aMRHA\u0026id=T2pQBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U3WHMp8Lnm2P_huYC6BuCzXQWMbDQ","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Applying_to_an_area_of_skin_from_which_r.pdf?id=T2pQBAABERAJ\u0026output=pdf\u0026sig=ACfU3U2Ugaex-lLnuPNbipGiPv42Bd6Vpw"},"sample_url":"http://www.google.com/patents/reader?id=T2pQBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>